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ABSTRACT 
 
Clinico-radiological predictors of favorable outcome and quality of life 
in patients undergoing percutaneous sclerotherapy for slow flow 
vascular malformations 
BACKGROUND: 
Slow flow vascular malformations are one of the commonest soft tissue 
lesions in children and young adults. They include venous malformations 
(VM) and lymphatic malformations (LM). They cause significant morbidity 
in terms of cosmesis and functional impairment. Surgical resection is often 
incomplete, and proximity to vital deeper structures are a common reason for 
incomplete resections. Sclerotherapy is a treatment method by which a 
sclerosant is injected into the cystic vascular spaces. Percutaneous 
sclerotherapy has become the standard of care for slow flow vascular 
malformations worldwide. 
AIMS & OBJECTIVES: 
The aim of this study was to objectively evaluate the improvement in 
symptoms and quality of life in patients receiving percutaneous sclerotherapy 
for slow flow vascular malformations. Additionally, the study attempted to 
identify clinical and radiological predictors of a favorable outcome in 
patients undergoing this procedure.  
MATERIALS & METHODS: 
Patients who were referred to the interventional radiology clinic for the first 
time were included in this study after informed consent. Sodium Tetradecyl 
Sulfate (STS) was injected into the venous malformations. STS and 
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bleomycin were injected into the lymphatic malformations. A modified form 
of a standardized questionnaire (SF-36) was used to assess the quality of 
health life. The questionnaire was administered to the patient prior to the 
sclerotherapy and at three-time points after sclerotherapy- day1, day 3 and 
day 7. The basic demographics of the patient as well as specific radiological 
features such as type and the extent of involvement was used for analysis. 
 
RESULTS: 
There were 53 patients, with age ranging from 2-47 years. There were 23 
males and 30 females. There were 37 patients with VM and 16 with LM.  
There was a statistically significant difference in the means of the quality of 
life pre-sclerotherapy, and day 7 post sclerotherapy scores (p<0.0001). There 
was also a statistically significant association between the earlier age of 
presentation with better quality of life (p=0.019, Pearson coefficient of 0.320, 
suggesting moderate correlation). The analysis also revealed a transient 
worsening of the quality of life scores immediately following sclerotherapy 
(day 1) with improvement at day 7. The other parameters such as the plane of 
the malformation, type, pre-treatment size, number of needles did not have a 
statistically significant association with the quality of life. There was no 
significant difference in quality of life between the patients with VM or LM.   
CONCLUSION 
Sclerotherapy for slow flow vascular malformations is a safe and reliable 
way to treat patients. Earlier age of first session of sclerotherapy was 
associated with a significantly better outcome in terms of quality of life. 
There was a significant association between the volume of foam sclerosant 
 3 | P a g e  
 
injected and better quality of life. The use of sclerosant should be limited in 
the head of neck region (lip and tongue) where there is high risk of tissue 
necrosis. Patients should be informed of the natural course of events, where 
there is a transient worsening of the symptoms immediately after 
sclerotherapy due to the local inflammatory response.  
 
KEYWORDS: 
Sclerotherapy, slow flow vascular malformations, venous malformation, 
lymphatic malformation, quality of life. 
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INTRODUCTION 
 
Slow flow vascular malformations are one of the most common soft tissue 
lesions in children, adolescents and young adults. They cause significant 
morbidity not only in terms of cosmesis and functional impairment, but can 
also be a cause for mortality, if in relation to vital structures. Surgical 
resection is often incomplete, and proximity to vital deeper structures can 
often impair complete resection. Hence, sclerotherapy or injection of 
sclerosant into these cystic vascular spaces has become the standard of care 
worldwide. 
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AIMS AND OBJECTIVES 
 
 
 
This study had the following aims and objectives: 
 
1. To objectively evaluate the improvement in symptoms and quality of 
health life in patients receiving percutaneous sclerotherapy treatment for 
slow flow vascular malformations. 
 
 
2. To identify and evaluate radiological and clinical predictors of outcomes 
(favourable and unfavourable) in patients undergoing this treatment 
procedure. 
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LITERATURE REVIEW AND BACKGROUND 
 
INTRODUCTION 
 
Vascular malformations have often been misdiagnosed in the past and 
continue to be even today. A lot of confusion exists even on the 
nomenclature today.  
Most of the vascular malformations can be diagnosed using a good history 
taking and thorough clinical examination with focussed imaging to plan or 
discern its uncertain deeper extension. 
Ultrasound and colour doppler was considered as the primary modality for 
assessment of lesions or tumours of vascular origin because of its wide 
availability and ease of use. However it has inherent limitations such as 
limited field of view, reduced penetration for deep lesions and operator 
dependency (1). 
This has been largely been replaced by MRI examination, along with 
gadolinium enhanced scans which have become the investigation of choice 
for most of these malformations, which has the advantages of imaging in 
three dimensions, which is useful in planning and also to know its relation to 
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vital deeper structures. The type of vascular malformation determines the 
type of treatment or therapy that is given (2). 
The commonest term that continues to be used today among clinicians and 
other specialists is ‘haemangioma’, which is a non-specific term. Confusion 
about the nomenclature and the imaging guidelines is largely responsible for 
the faulty diagnosis and improper treatment which can cause significant 
morbidity to the patients (3). 
Vascular malformations and tumours alike are comprised of a wide array of 
lesions that can involve any part of the body. The beginning of the 
classification of these vascular malformations began in 1983 in a landmark 
article by Mulliken et al which first described them in terms of histology of 
the type of the endothelial proliferation (4). 
 
 
ETIOLOGY 
 
The aetiology or causative factor for most of these vascular malformations 
remains largely unknown. A few of them have been associated with 
syndromic associations, associated with specific gene mutations which are 
primarily collagen or reticulin related, which have been earlier elucidated (5). 
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There are a few factors which aggravate these slow vascular malformations: 
1. Infection 
2. Trauma  
3. Hormonal change 
4. Radiation 
5. Connective tissue disease 
These specific etiological factors are known to aggravate the already existing 
lesions, because of which the patient might become symptomatic only after 
these events. Thus, in most of these patients they give a history of these prior 
aggravating factors and they associate these conditions as a causative agent 
for them. 
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PATHOPHYSIOLOGY OF VASCULAR MALFORMATIONS
 
Figure 1 
The vascular malformations develop from the mesoderm. The cancellous 
network of capillaries in the foetal period is responsible for differentiation  
 
Abnormal regression of any one of those structures is responsible for various 
vascular malformations. 
The above illustration describes (6) the pathophysiology of vascular malformations 
when arrest of development occurs in the different stages of vasculogenesis.  
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If there is an abnormal connection between the arterial and venous 
components – this leads to an arteriovenous fistula. If there is failure of 
regression of the venous, lymphatic or capillary components of the 
cancellous network of capillaries – leading to various malformations. 
The knowledge of the basic pathophysiology of these vascular malformations 
is important as it guides in the management of them. 
 
ISSVA CLASSIFICATION OF VASCULAR MALFORMATIONS 
(2017) 
 
 
Two major classes had emerged from the Mulliken and Glowacki 
classification of vascular anomalies- haemangiomas and vascular 
malformations. However with the advent of advanced colour doppler and 
MRI examinations in the 1990s, there was new understanding of these 
vascular malformations (4). 
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The current classification that is accepted worldwide is International Society 
for Study of Vascular Malformations (ISSVA) in 2017, which is 
comprehensive and includes most of the malformations and tumours of 
vascular origin (5). 
                                                         VASCULAR ANAMOLIES 
Vascular 
tumours 
                                        Vascular malformations 
Simple  Combined Syndromic 
association 
Benign Capillary 
Lymphatic 
Venous 
Arteriovenous 
malformations 
Arteriovenous fistulas 
 
CVM 
CLM 
CAVM 
CLAVM 
LVM 
CLVM 
Klippel 
Trenaunay 
 
Parkes weber 
 
Servelle 
martorelle 
Mafucci  
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Locally 
aggressive 
Kaposiform 
hemangioendothelioma 
Kaposi sarcoma 
  
Malignant Angiosarcoma 
 
  
 
 
The benign vascular tumours are further subclassified into (8):  
BENIGN VASCULAR TUMOURS 
Congenital haemangioma 
- Rapidly involuting 
- Non involuting 
- Partially involuting 
Tufted angioma 
Spindle cell haemangioma 
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Epithelioid haemangioma 
Pyogenic granuloma 
 
LOCALLY AGGRESSIVE OR BORDERLINE TUMOURS 
Kaposiform haemangioendothelioma 
Retiform haemangioendothelioma 
Composite haemangioendothelioma 
Kaposi sarcoma 
Papillary intralymphatic angioendothelioma 
MALIGNANT VASCULAR TUMOURS 
Angiosarcoma 
Epithelioid hemangioendothelioma 
The simple vascular malformations are further classified into capillary, 
venous, lymphatic broadly which have distinct entities in each: 
CUTANEOUS VASCULAR MALFORMATION 
Cutaneous or mucosal with  
         -Soft tissue overgrowth 
        -With CNS or ocular anomalies 
        -with microcephaly capillary malformation 
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       -Megalencephaly capillary malformation polymicrogyria 
Hereditary haemorrhagic telangiectasia 
Cutis marmorata congenital 
Nevus simplex / Angel kiss / Stork bite 
 
Lymphatic (8) 
SIMPLE VASCULAR MALFORMATIONS 
Lymphatic Malformations 
Microcystic 
Macrocystic 
Mixed  
Generalised Lymphatic anomaly 
Gorham stout disease 
Primary lymphedema 
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Simple vascular malformations – II 
Lymphatic malformations 
Common (cystic) lymphatic anomaly 
                   - Macrocystic LM 
                   - Microcystic LM 
                   - Mixed LM  
Generalised lymphatic anomaly 
LM in Gorham stout disease 
Primary Lymphedema 
Chanel type LM 
Lymphedema is further classified as: 
PRIMARY LYMPHEDEMA 
Nonne Milroy syndrome 
Primary hereditary lymphedema 
Hypotrichosis  lymphedema telangiectasia 
Primary lymphedema with myelodysplasia 
Microcephaly with or without chorioretinopathy 
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Venous malformations (8) 
Simple vascular malformations III 
Venous malformations 
Common VM 
Familial VM cutaneous – mucosal (VMCM) 
Blue rubber bleb nevus (bean) syndrome VM 
Glomovenous malformation 
Cerebral cavernous malformation 
Others 
 
Arterio-venous malformations with an arterial component in the 
malformation – which are a different entity – should be embolised with 
alcohol. 
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Simple vascular malformations IV 
           Arteriovenous malformations  
Sporadic  
In HHT 
In CM – AVM 
          Arterio-venous fistula (congenital) 
Sporadic 
In HHT 
Others 
 
A combination of any of these can occur, whereby it is classified as 
combined vascular malformation (8). 
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Combined vascular malformations 
CM + VM Capillary - venous malformation CVM 
CM + LM  Capillary - lymphatic 
malformation 
CLM 
CM + AVM Capillary - arteriovenous 
malformation 
CAVM 
LM + VM Venous – lymphatic VLM 
CM + LM + 
VM 
Capillary - Lymphatic - venous 
malformation 
CLVM 
CM + LM + 
AVM 
Capillary - Lymphatic - 
arteriovenous malformation 
 CLAVM 
CM + VM + 
AVM 
Capillary -venous - arteriovenous 
malformation 
CVAVM 
CM + LM + 
VM + AVM 
Capillary -lymphatic - venous - 
arteriovenous malformation 
CLAVM 
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There are syndromic associations which are associated with vascular 
malformations which are separately classified according to ISSVA guidelines 
(8). 
 
Vascular malformations associated with other anomalies 
Klippel – 
Trenaunay  
CM + VM + limb overgrowth  
Parkes Weber CM + AVF + limb overgrowth 
Servelle – 
Martorell  
Limb VM + bone undergrowth 
Sturge- Weber  Facial + leptomeningeal CM + Eye anomalies + bone 
/soft tissue overgrowth 
Mafucci  VM + spindle cell haemangioma + multiple 
enchondromas 
CLOVES LM + VM + CM + AVM + lipomatous overgrowth 
Bannayan- Riley- 
Ruvalcaba  
AVM + VM + macrocephaly + lipomatous 
overgrowth  
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A few of these vascular anomalies cannot be grouped under any of the 
categories and are grouped under unclassified category in the ISSVA 
classification (9). 
 
Provisionally unclassified vascular anomalies 
Verrucous hemangioma 
Angiokeratoma 
Kaposiform lymphangiomatosis (KLA) 
PTEN (type) hamartoma of soft tissue  
Multifocal lymphangioendotheliomatosis with thrombocytopenia 
 
Thus, although the classification is extensive, a broad division of these 
vascular anomalies (other than tumours) for therapy is that determining if any 
of these lesions have an arterial or fast component associated in these 
specific conditions. 
If any of them have an arterial component – which is determined by 
ultrasound and doppler study, then the management would primarily consist 
of embolization with alcohol (10). 
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Slow flow vascular malformations – lymphatic, capillary, venous and a 
combination of them is diagnosed by the absence of arterial component on 
ultrasound and doppler screening. Treatment for these slow flow 
malformations is primarily done by injecting a sclerosant into these vascular 
spaces. The sclerosant induces intimal fibrosis and induces an inflammatory 
response which causes near total obliteration of these vascular spaces (11). 
Treatment of these various types of slow malformations requires a 
multidisciplinary approach with paediatric and plastic surgeons, 
anaesthetists, diagnostic and interventional radiologists , critical care and 
vascular surgery (12). Most of these vascular malformations should be 
managed in a tertiary level centre, as it requires expertise of all these 
specialists, and a combined decision regarding patient management is done. 
HEMANGIOMAS  
 
Haemangiomas are the commonest vascular tumours (13). The 
pathophysiology of these lesions is disorderly endothelial cell proliferation 
with abnormal angiogenesis. 
These generally are not visualised at birth. Two types of haemangiomas are 
generally described – congenital and infantile types which are different in 
their clinical presentation (13). 
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Congenital haemangiomas are at maximal size at birth and have three types 
of behaviour: 
1. Rapidly involuting haemangiomas – involute rapidly  
2. Partially involuting – do not regress completely 
3. Non involuting  
Infantile haemangiomas are one of the commonest vascular tumours of 
infancy – more commonly found in preterm infants with a female pre-
ponderance (3:1) with an incidence of 23 % in low birth weight neonates. 
Head and neck region is the most common region to be affected (>60%) (14) 
with more than 80% being solitary. 
The molecular marker for infantile haemangioma is glucose transporter 1 
(GLUT-1), which is characteristically absent from congenital haemangiomas 
(13). 
Radiological findings on ultrasound include echogenic soft tissue component 
with an arterial or fast component noted within the mass. CT is generally not 
indicated in diagnosis or management, with an additional risk of radiation 
exposure. 
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MRI is useful in delineating the anatomical structures such as the airway, 
vital neurovascular proximity and has the become the standard of care before 
planning pharmacological treatment or a minimally invasive surgical 
procedure (13). 
Haemangiomas are the commonest vascular tumours which regress in 
childhood. Other tumours which have been described have borderline or 
malignant behaviour, where there’s a risk of the Kasabach-Merritt 
phenomenon – in which there’s a risk of a consumptive coagulopathy and 
subsequent disseminated intravascular coagulopathy with life threatening 
consequences. Hence early assessment of vascular tumours are essential (7). 
 
VASCULAR MALFORMATIONS 
 
Vascular malformations are generally occur from birth, although most of 
them may not be symptomatic at birth. A variety of factors during early 
childhood and development lead to overt clinical manifestations of these 
malformations. A good history combined with a clinical examination 
supplemented with appropriate imaging is necessary for diagnosis. They may 
occur sporadically or as part of certain syndromes in combination with other 
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vascular malformations. Described below are specific features of each 
malformation: 
SPECIFIC FEATURES OF EACH SUBTYPE 
CAPILLARY MALFORMATIONS 
 
Capillary malformations, are most commonly referred to loosely as a ‘port 
wine stain’. They usually occur as sporadic findings, however some of them 
maybe associated with sinister syndromes like Sturge weber syndromes 
which is associated with classical findings such as facial angioma, seizures, 
glaucoma, mental retardation and arterio-venous malformation in the brain. 
Thus an isolated capillary malformation must not be taken lightly and should 
be investigated to rule out systemic abnormalities associated with fatal 
syndromes (9). 
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Figure 2 
Above is a gentleman with Sturge Weber syndrome. Clinical photograph 
showing facial cutaneous malformation (port wine stain). T1W axial MRI 
image showing right sided cerebral hemiatrophy (6) 
 
Most of these patients present with a flat macule, which is pink in colour, 
blanches on application of pressure. If the location of such a lesion occurs on 
the face, it warrants a MRI study of the brain, to look for arterio-venous 
malformations of the underlying brain, associated with a gyral pattern of 
calcification, classically described as tram-track calcification on a plain CT 
study of the brain in these patients. 
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The standard of care is pulsed dyed laser, which acts by a mechanism of 
photo-thermolysis, where haemoglobin selectively absorbs laser light, 
thereby converting it to heat, causing blood to coagulate. Significant relapses 
can occur, alternative therapies include pulse light and photo-dynamic 
therapy (15). Sclerotherapy is generally not used in capillary malformations. 
 
 
VENOUS MALFORMATIONS 
 
Venous malformations are most common type of slow flow vascular 
malformations. Hamburg et al classified it as truncular, and extra-truncular 
with the distribution following a near pattern of symmetry in the form of 
head and neck constituting 40%, truncal being 20% and extremities being 
40%. 
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Figure 4: Bluish discoloration of 
the oral mucosa in a patient with 
bleeding following eating. 
Venous malformation of the 
entire oral mucosa is seen. 
 Figure 3: Soft tissue swelling and cosmetic disfigurement due an extensive trans-
spatial venous malformation in this patient with serial number 13 in the current study.                                             
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Figure 5: Serial number 17 patient in this study – plain radiograph of the left 
forearm showing soft tissue density with a few calcifications within them. Fat 
suppressed coronal STIR images show hyperintense spaces with multiple 
phleboliths, appearing as STIR hypointense discrete foci. 
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Figure 5: Serial 23 patient in this study – 13-year-old child with right thigh 
swelling – fat supressed coronal STIR images showing multiple hyperintense 
spaces in the posterior intramuscular component, with multiple phleboliths. 
Corresponding fluoroscopy image during sclerotherapy showing diffuse nature of 
this VM. 
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CLASSIFICATION OF VENOUS MALFORMATIONS (13,16) 
 
 
 
 
 
 
 
 
The classification of venous malformations is essentially based on the 
phlebography appearance of these lesions once contrast is injected: - 
Type I denotes an isolated venous malformation with no visible venous 
drainage. 
Figure 6:The updated ISSVA classification (2017) for venous malformations 
(13) is based on the type of cystic spaces with the venous drainage evident on 
DSA.  
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Type II denotes normal sized venous drainage nearby. 
Type III denotes enlarged venous drainage. 
Type IV essentially consists of enlarged dysplastic venous channels which 
are ectatic. 
This classification is important in management of these lesions, as the 
amount of sclerosant, use of a proximal tourniquet for proximal venous 
occlusion is dependent on the type of the venous malformation. 
 
Clinically they present as bluish lesions that increase in size with any 
increase in pressure such as Valsalva, or cough impulse. They also cause 
bluish discoloration. They can be classified as focal or diffuse, with diffuse 
involving multiple soft tissue planes. These diffuse venous malformations 
often require multiple sessions of treatment, and often recur (17).  
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Figure 7: 9-year-old child with diffuse VM of the left lower limb - plain 
radiograph of the left knee showing multiple soft tissue calcifications in 
patient with known VM – phleboliths because of prior thrombophlebitis 
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.          
 
 
Figure 8: Serial 8 patient in the current 
study is a 15-year-old child, VM of the left 
lower limb -with intramuscular STIR 
hyperintense cystic spaces in the left calf 
with a few hypointense foci suggestive of 
phleboliths 
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The symptoms they cause could be due to regional mass effect causing 
cosmetic effect or an obstruction of the airway in the head and neck region, 
or a high risk of thrombo-embolism due to dysplastic veins in the lower 
limbs. Close proximity to a large synovial joint (e.g.: knee) can cause 
hemosiderotic arthropathy which predisposes to early degenerative changes 
within the joint leading to restriction of range of movement along with pain 
(13). 
Conventional radiography of these lesions reveals multiple calcified 
phleboliths which represent calcified thrombi because of delayed venous 
clearance due to previous thrombophlebitis. 
MRI is the primary imaging modality for assessing venous malformations. 
T2-weighted short tau inversion recovery (STIR) imaging provides the best 
sequence for assessing the extent of the VM and the vascular flow rate and 
will demonstrate a soft tissue with phleboliths. Additionally, lesions with 
large vascular channels appear cyst-like, hyperintense and septated, whereas 
lesions with smaller vascular channels are more solid with intermediate 
signal intensity. On T1 weighted imaging, the lobulated area has variable 
signal intensity with regional fat hypertrophy. Following contrast injection, 
T1 weighted imaging demonstrates homogeneous or heterogeneous 
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enhancement within the lesion MRI is also useful in determining adjacent 
tissue involvement, as vascular malformations can be well circumscribed or 
infiltrate into adjacent soft tissue or the lymphatic system. 
Conservative management of these venous malformations include graded 
compression stockings (13,16) used to reduce pain and deformity along with 
slowing the progression of the disease, However these are not definitive 
treatment modalities.  
The definitive treatment of venous malformations include sclerotherapy with 
agents like sodium tetradecyl sulphate (STS), polidocanol and absolute 
alcohol, each of which have their own advantages and disadvantages (18). 
In extensive venous malformations, in which there is no symptomatic 
improvement despite sclerotherapy or other conservative methods-m-TOR 
inhibitors (mammalian target of rapamycin) such as Sirolimus have shown 
promising results, although long term effects are not known  & the data is 
based on small case series with no large scale randomised controlled trials 
(19). 
LYMPHATIC MALFORMATIONS 
 
Lymphatic malformations (LMs) account for approximately 2.8/100,000 
hospital admissions and present before the age of 2 years in 90% of cases. 
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They are low-flow vascular malformations consisting of malformed 
lymphatic channels within the lymphatic system and are cystic in nature. 
LMs can be divided by size into macrocystic (>0.1 cm) and microcystic 
(<0.1 cm) groups. Typically, microcystic LMs are more common and present 
later than macrocystic LMs, which are usually present at birth (20). 
The appearance of LMs depends on their location. Superficial LMs are 
typically skin-coloured masses and ballotable on palpation, whereas they 
appear as red or yellow blisters when involving mucous membranes. LMs 
have a predilection for the head and neck with 70–80% of cases in this 
location, and an additional 20% occurring in the axilla and a minority of 
cases occurring in the superior mediastinum, mesentery, retroperitoneum, 
pelvis and lower limbs (21). They typically grow slowly, although rarely 
LMs can rapidly expand in size after intralesional haemorrhage or 
superinfection. In these cases, LMs can become life threatening if they  cause 
adjacent mass effect and compression of vital structures (20). 
 
Podoplanin D2-40 is a molecular marker that is positive in lymphatic 
endothelium, and may be used to differentiate between other vascular 
malformation, when there are overlapping clinical features (16). 
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Figure 9: Microcystic lymphatic malformation with recurrence following 
surgery with non-healing ulcer, lymphatic ooze and discoloration in a 13-
year-old boy, who had been referred to the interventional radiology clinic. 
He was offered m-TOR inhibitor- sirolimus in view of the diffuse 
microcystic LM. 
 40 | P a g e  
 
 
 
Figure 10: Vesicular appearance of microcystic lymphatic 
malformations- note scar of prior surgery in a 13-year-old boy referred 
to the interventional radiology clinic. Sirolimus was offered. 
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Figure 11 : The young child in the Fig 11 clinical picture – corresponding 
STIR axial and coronal MRI images shows a microcystic LM with STIR 
hyperintensities in the skin and subcutaneous tissues of the medial thigh. 
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Figure 12:Serial number 16 of 3-year-old child in thus study with a large swelling in 
the right side of the neck - corresponding T2w images show a macrocystic LM with 
fluid-fluid level and multiple septae. Ultrasound images show a cystic lesion with 
dependent low-level echoes. 
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The evaluation of LMs is highly reliant on imaging to discern the size and 
characteristics of the lesion, as these directly dictate treatment strategies and 
outcome. As with other vascular anomalies, MRI is the best imaging 
modality for diagnosing and defining LMs because of its superior soft-tissue 
resolution. Microcystic and macrocystic LMs have distinct appearances on 
MRI owing to the size difference in their cystic component. On T2 weighted 
MRI and T2 weighted STIR imaging, LMs are typically well defined, 
lobulated and hyperintense T1 weighted imaging of macrocystic LMs 
typically shows a septated cystic mass that ranges from hypointense to 
isointense and that is often heterogeneous owing to proteinaceous fluid or 
fluid–fluid levels. Post-contrast T1 weighted images are also important tools 
for differentiating macrocystic LMs from VMs, as LMs typically do not 
enhance after contrast injection unlike VMs.  By contrast, the small cystic 
compartments of microcystic LMs appear as diffuse hypointensity on T1 
weighted imaging and diffuse hyperintensity on T2 weighted imaging. 
 
Sometimes, other imaging modalities may be needed to further define the 
lesion or differentiate an LM from other vascular anomalies. Ultrasound is a 
particularly useful method for discriminating LMs from VMs. Macrocystic 
LMs typically manifest as anechoic spaces divided by septa, whereas 
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microcystic LMs appear hyperechoic owing to their small cavity size. 
Ultrasound is also useful for evaluating prior haemorrhage and demonstrating 
fluid–fluid levels. In addition, Doppler examination of LMs demonstrates no 
flow through the lesion, which helps distinguish them from VMs, where flow 
is seen in 85% of cases. Conventional radiology can also be useful in the 
work-up of large LMs near bone, as they can cause bony hypertrophy and 
bone warping.  Although usually not necessary for the diagnosis of LMs, CT 
imaging demonstrates a fluid-filled low-attenuation mass with little contrast 
enhancement. In cases of intralesional haemorrhage, fluid–fluid levels may 
be visible on CT.  Treatment indications for LMs are like those of other 
vascular malformations, with lesions located in life-threatening areas such as 
retropharyngeal LMs requiring prompt treatment.  
Any LM that has experienced a haemorrhagic or infectious event should also 
be treated and requires antibiotics and steroids in addition to definitive 
treatment of the LM. Relative indications for treatment include patient 
discomfort, impaired mobility, aesthetic dissatisfaction or any other cause 
that significantly impairs quality of life. 
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FAST FLOW MALFORMATIONS 
 
The vascular malformations included here are arteriovenous malformations 
and arteriovenous fistulae. Although these can commonly occur sporadically, 
they can occur in combination with other vascular malformations or in 
association with other malformations. These can give rise to various 
syndromes. The Klippel-Trenaunay syndrome is the commonest. 
 
ARTERIO-VENOUS MALFORMATIONS: 
 
These are abnormal connections or shunts between arteries and veins without 
any network of capillaries between them. The cluster of abnormal 
connections or shunts in these malformations is called a nidus (16). In an 
arterio-venous fistula, there’s shunting of blood through a single arterialised 
vein.  
AVMs can occur anywhere in the body and thus have varied clinical 
manifestations depending upon the local effects it causes. AVMs generally 
present as pulsatile masses, with increased local warmth, generally associated 
with a palpable thrill if it is superficially located. Schobinger classification 
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accurately describes the various stages of an AVM and is thus helpful in 
directing clinical management. 
 
 SCHOBINGER CLASSIFICATION OF AVMs 
Stage Description  Findings 
I Quiescence Cutaneous blush & 
warmth 
II Expansion Bruit or thrill with 
increasing size, 
pulsation, no pain 
III Local destruction Pain, bleeding, 
infection, skin necrosis 
or ulceration 
IV Decompensation High output cardiac 
output failure 
 
AVMs in the final stage can cause high output cardiac failure due to rapid 
arterio-venous shunting which increases the cardiac pre-load. AVMs 
generally are symptomatic during puberty when there’s a hormonal influence 
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on angiogenesis and during pregnancy when there’s a rapid increase in blood 
volume. Trauma and incomplete endovascular treatment with embolic agents 
can cause an increase in pro-angiogenic factors and thus worsening of the 
clinical symptoms. 
 
Two syndromes which are commonly associated with AVMs are hereditary 
haemorrhagic telangiectasia (HHT), which are associated with multiple 
telangiectasias of skin and mucosa. 
 
  
SCLEROTHERAPY FOR SLOW FLOW VASCULAR 
MALFORMATIONS 
 
Foam sclerotherapy has become the standard of care for slow flow vascular 
malformations (venous, lymphatic, venolymphatic). Several sclerosants have 
been used for slow flow vascular malformations, but the most widely used in 
our centre is sodium tetradecyl sulphate 3% by volume and bleomycin if 
there is a lymphatic component involved. 
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WORKUP FOR PATIENTS PRIOR TO SCLEROTHERAPY 
A thorough history and clinical examination is performed with specific 
regard to their predominant symptom. Then an ultrasound or doppler is done 
to confirm the presence of cystic compressible vascular spaces with absence 
of arterial flow within the lesions. MRI is done in all patients to accurately 
delineate the soft tissue extent of the malformation with specific regards to 
the neurovascular proximity, airway in head and neck lesions and intra-
osseous or intra-articular extensions as all of them have a bearing on the 
outcome. 
 
 
Figure 13 A practical algorithm used by interventional radiology for 
identifying the diagnosis and the type of treatment using ultrasound and 
doppler examination (6) 
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Basic blood investigations are done such as haemoglobin, blood borne viral 
status, bleeding parameters such as prothrombin time, partial thromboplastin 
time, and platelet count. 
 
A recent recommendation is D-dimer levels particularly patients with large 
lesions, as there is usually associated localised intravascular coagulation (22), 
which can progress to disseminated intravascular coagulation in large 
lesions. Thus, a close monitoring of patients should be done in the ward. Any 
prolonged bleeding episodes must be dealt with caution.  
 
D dimer can also be a used a lab predictor of future recurrence of these 
lesions or a reliable predictor of outcome. Leung et al (22) have shown that 
an increase in D dimer post procedure generally favours a better outcome  
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PROCEDURE – SCLEROTHERAPY  
 
Sclerotherapy has become the standard of care for management of slow flow 
vascular malformations. The basic principle of sclerotherapy is that it induces 
an inflammatory response, which results in pro-fibrotic growth factor release, 
which ultimately leads to intimal fibrosis, thus leading to decrease in the size 
of the cystic spaces which reduces the patient’s symptoms. 
Generally multiple sessions of sclerotherapy are needed for a complete 
response, with a minimum interval of 6 weeks between sessions to induce 
intimal fibrosis. In our centre, with most patients have a median time interval 
varying between 3 months to a year. Most patients require a minimum of 3-4 
sessions of sclerotherapy, although it depends on the type, location and 
largely on the size of the lesion prior to therapy. Larger lesions may require 
multiple sessions, although extensive lesions may benefit from sirolimus (m-
TOR inhibitors).  
The primary endpoint of the treatment of these malformations for 
sclerotherapy is reduction in the degree of the symptoms, especially in the 
extremities, where these vascular malformations tend to cause debilitating 
pain restricting their activities of daily living. The endpoint of therapy for 
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malformations in the head and neck region include improvement in the 
cosmesis or improvement of their quality of life. 
 
The decision for repeat sclerotherapy is also determined prior to the 
procedure, by assessing the presence of cystic, compressible spaces with 
absence of arterial component which would be designated as spaces 
amenable for sclerotherapy. 
 
 
The procedures are carried out under general anaesthesia as these sessions 
are painful due to the immediate action of the sclerosant on the endothelial 
cells. All procedures were carried out in a digital subtraction angiography 
suite (Artis Ziehm© biplane Seimens®) under strict aseptic precautions. 
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 Based on the location, after anesthetising the patient a tourniquet may be 
used especially in extremity venous malformations, to make the cystic spaces 
more prominent before access with a 21G needle. The cystic spaces are 
marked out on the skin with superficial transducer probe (7.5-10 MHz) 
Figure 15:  Artis Ziehm© biplane Seimens® apparatus used for sclerotherapy. 
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machine.              
 
 
 
 
The venous malformations are accessed under strict aseptic precautions with 
either a scalp needle (22 G) or a lumbar puncture needle (21 G) based on 
Figure 16: Under aseptic precautions ultrasound being used for accurate 
localisation of the slow flow vascular malformation 
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how superficial or deep the lesion for access. Generally multiple needles are 
placed in the cystic spaces to equally distribute the sclerosant foam volume 
into the slow flow vascular malformation. 
  
 
 
  
 
Figure 17:  22G LP needle for access to deeper lesions 
Figure 18: 24G scalp needle used for superficial access 
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Access into the cystic spaces of the venous malformation under direct 
visualisation of ultrasound  
Figure 19: Cystic spaces accessed with 22G LP needle under USG guidance 
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 Figure 20 :  Figure showing free flow of blood confirming the location 
of the needle within the slow flow vascular malformation.  
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Minimal saline infused into the extension of the needle to prevent blood from 
clotting in the tract prior to injection. 
Figure 21: Saline infusion into the tubing to prevent the clotting of 
blood, after free backflow was identified. 
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After accurately placing the needle in the cystic spaces of the slow flow 
vascular malformation using ultrasound guidance, a small amount of contrast 
is injected with a ‘Roadmap’ mode chosen on the DSA machine. Contrast is 
injected till there is faint opacification of a draining systemic vein. This 
serves as a surrogate marker for the dose of the sclerosant foam to be 
injected. 
 
Figure 22: 3 way & stop cock used to prepare foam 
sclerosant.  
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Figure 23:  Venogram or phlebogram (using the ‘Roadmap’ setting in DSA) 
through the venous malformation to look for type of venous drainage and to 
calculate approximate dose of sclerosant. Above is type IV venous malformation 
with dysplastic large venous channels with a large normal draining vein cranially. 
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Figure 24:  Inverted flouro-save image of venous malformation with multiple 
needles within it with contrast being injected to determine the type of venous 
malformation and the approximate dose to be injected into each needle . Also note 
multiple phleboliths which are calcified thrombi in the venous malformation in 
the left foot which are diagnostic of a venous malformation on plain radiographs. 
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Figure 25:  DSA image of a venous malformation being injected through 
multiple needles. Note the presence of air in the foam appearing as 
hyperdense on the negative DSA image. 
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If it is a large venous or veno-lymphatic malformation, blood or lymph is 
aspirated to decrease the overall volume of the malformation, so that the 
relative concentration of the sclerosant injected is much higher, to act on the 
endothelial cells in the wall of the slow flow vascular malformation. 
 
Foam sclerotherapy is a concept where there is an equal amount of air 
aspirated through the syringe and mixed with the liquid sclerosant to form a 
foam using a three-way and another syringe. This serves two purposes. It 
reduces the total amount of the actual sclerosant being injected, and has a 
larger surface area of distribution, thus increasing the efficacy of the 
sclerotherapy. 
 
Post-injection, the needles are usually left in place for a period of 5 to10 
minutes, following which they are removed. Slow flow vascular 
malformations which are superficial and are in the head and neck region tend 
to increase in size post-sclerotherapy which resolve usually by 3 days. The 
amount of immediate post procedure pain also increases as there is 
immediate acute inflammatory response within, leading to pain, swelling, 
which can be managed with simple NSAIDs in the ward. 
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SCLEROSANTS USED FOR SCLEROTHERAPY 
Multiple agents have been used in the past as sclerosants for slow flow 
vascular malformations. By far the most common sclerosant agent used is 
sodium tetradecyl sulphate (used as 3% weight per volume). The other 
sclerosants used are: 
 
BLEOMYCIN 
Bleomycin was initially developed as an anti-tumour antibiotic which acts at 
the cellular level to inhibit DNA synthesis. However, in recent studies it was 
shown to induce non-specific inflammatory reaction on the endothelial cells. 
It was first used on macrolymphatic malformations which was earlier called 
cystic hygroma. In a comparative study comparing alcohol and Bleomycin 
stated that alcohol is more effective in deeper lesions and Bleomycin is 
useful in superficial lesions. 
 
Bleomycin in our department and institution is used primarily when there’s a 
lymphatic component in the slow flow vascular malformation. It is primarily 
available as powder which is then reconstituted using normal saline to the 
desired dilution. 
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Figure 26: Bleomycin used in our current practice   
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 SODIUM TETRADECYL SULPHATE: 
 
Sodium tetradecyl sulphate is a commonly used sclerosant in clinical practice 
for other indications such as varicose veins. It is an anionic detergent agent 
(23) that acts by destroying or meddling with the lipid bilayer of the cell 
membrane. It also acts by denaturing intracellular proteins such as clotting 
factors and thereby inducing thrombosis of these vascular spaces, thus 
inducing fibrosis and decrease in size of the lesion (23). It is one of the most 
widely used sclerosing agents used worldwide for sclerotherapy for venous 
malformations. It has one of the best safety profiles with very rare risk of 
rhabdomyolysis and subsequent haemoglobinuria, which can cause renal 
failure. Hence all patients post procedure are advised adequate hydration, 
with strict monitoring of fluid intake and urine output.  
 
Sodium tetradecyl sulphate is commonly available as a 3% w/v solution 
which is diluted with an equal amount of air to create foam sclerosant, which 
is then used for therapy. 
 
The upper limit for usage is 1 ml/kg of liquid sclerosant in total for the entire 
patient. Thus, in children and infants with slow flow malformation in the 
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head and neck region, with proximity to the airway, dose is calculated prior 
to the procedure based on their weight, as excess dose can cause increased 
risk which can cause complications with increased hospital stay. 
                  
 
 
ETHANOLAMINE OLEATE 
 
Ethanolamine oleate is a cytotoxic agent which is a mixture or emulsion of 
fatty acids which primarily acts on the endothelial cells, thus inducing 
thrombosis of the vascular spaces. This is not used in India currently due to 
its non-availability. It has a decent safety record with the reported 
complications being skin necrosis and ulceration which are observed in less 
than 5 percent of patients. 
Figure 28: STS foam used in our practice   
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 OK 432 (PICIBANIL) 
 
Picibanil is bacterial origin antibiotic which primarily acts as an immune-
stimulant, which causes local increase in the cytokines, thereby causing a 
local inflammatory response and endothelial cell damage and local 
thrombosis (23). It consists of a lyophilised mixture of low virulence group 
A streptococcus pyogenes mixed with benzyl penicillin (23).  
 
This has been widely used in the head and neck region with a safe profile of 
use which includes transient facial nerve paresis (23) and skin reaction. This 
is not currently available in India. 
 
 ABSOLUTE ETHANOL 
 
Absolute alcohol was used earlier in the management of slow flow vascular 
malformations. It acts primarily by denaturing cellular proteins, damage to 
the endothelial cell, thus inducing thrombosis within the lumen. Its use for 
slow flow vascular malformations has been abandoned due to the high risk of 
local complications which include skin ulceration, non-healing ulcers which 
result in bad cosmetic outcomes. This has a high risk of damage to the local 
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neurovascular structures up to 60% (23). Thus, its use is limited to direct 
percutaneous injections of the nidus in AVMs. 
 
DOXYCYLINE 
 
This widely available tetracycline antibiotic has been used widely in the 
treatment of lymphatic malformations. Exact mechanism of action remains 
unknown, although the possible mechanisms include inhibition of matrix 
metallo-proteinases (MMP’s) and inhibition of VEGF which causes 
angiogenesis and lymphangiogenesis. 
 
These have been primarily used in the management of macrocystic lymphatic 
malformations with no complications being reported after its use in literature 
(10). 
POLIDOCANOL 
 
Polidocanol is non-ionic agent which acts at the cell membrane level of the 
endothelial cells thereby causing endothelial damage and thrombosis. Its 
safety profile is like other sclerosants, and its usage is limited by the lack of 
availability.  
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PINGYANGMYCIN 
 
 Structurally like bleomycin (also called bleomycin A5), was discovered in 
china, hence the name. It is cost effective and the reported complications are 
transient fever and skin reaction. However, its use in India is limited by the 
lack of availability  
 
 
COMPLICATIONS OF SCLEROTHERAPY 
 
The most common complications following sclerotherapy are local skin 
reaction and pain which increase post-sclerotherapy. Careful counselling of 
patients is necessary, and they must be educated that the initial increase in 
pain and swelling is transient and is not a cause for alarm. The most severe of 
skin reactions include skin ulceration and necrosis and subsequent infection 
of necrotic tissues which can result in increased duration of hospital stays. 
 
The mechanism of haemoglobinuria in patients who have had sclerotherapy 
is the presence of free extracellular haemoglobin which depletes haptoglobin 
and nitric oxide which are normally free radical scavengers in the blood. 
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Figure 29:  Lip ulceration and bleeding in a lady 3rd day post sclerotherapy. This 
was managed conservatively with daily sterile dressings following which it 
resolved almost completely. 
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Figure 30:  Mild discoloration and 
ulceration in a 10-year-old child following 
sclerotherapy for a venous malformation 
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Figure 31:  Picture from the study done by Alomari et al (5) shows brownish early 
discoloration of urine following sclerotherapy. Note that the earlier urine was 
normal in colour. 
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Thus, urine colour and output must be carefully monitored in patients post 
sclerotherapy especially in large lesions into which higher volume of 
sclerosant has been injected. Oliguria defined as urine output < 1 mL/kg/hr, 
which is managed with a bolus of normal saline of 10-20 ml / Kg with use of 
loop diuretics such as furosemide (0.25 mg/kg). 
 
 
 
For gross haemoglobinuria, the IV fluid was modified to 5% dextrose 
in water with 75 mEq/L sodium bicarbonate at the maintenance rate to 
alkalinize the urine. Additional fluid was administered as lactated Ringer 
solution or normal saline. 
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MATERIALS AND METHODS 
  
Type of study: A prospective cohort study  
Population of study: 
The study population included patients which included children and adults 
who were diagnosed as having a slow flow vascular malformation (venous, 
venolymphatic or lymphatic) from the various departments within the 
Christian Medical College Vellore (CMC) hospital and were being referred 
to the interventional radiology department for sclerotherapy. 
Each patient was seen by a multidisciplinary team which consisted of 
interventional radiology, surgeons (vascular surgery, plastic surgery, 
paediatric surgery), anaesthetists. 
The patients were given an explanation regarding the nature of the vascular 
malformation that they have. The various treatment modalities were 
explained, and sclerotherapy was offered to them as a treatment option after 
explaining possible risks and benefits. 
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The patients in this study were included after they gave informed consent. As 
a significant group of patients in this study were children, the children above 
the age of 7 were given an explanation in simple vernacular language and an 
assent was taken. For infants and children younger than 7 years of age, 
informed consent for participating in this study was obtained from the 
parents. 
 
INCLUSION CRITERIA: 
Patients who have presented to CMC hospital for the first time and have been 
diagnosed with a slow flow vascular malformation, and who have not 
undergone any prior surgical treatment or sclerotherapy were included in the 
study. They also should give their consent to be treated by sclerotherapy 
procedure and be available for follow up questions and clinical evaluation. 
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EXCLUSION CRITERIA: 
Patients who had received prior treatment either sclerotherapy or surgery in 
any hospital or treatment centre were excluded from this study. Patients who 
did not consent to be part of this study were also excluded. 
 
SAMPLE SIZE CALCULATION:  
The sample size of the study was calculated using a statistician’s guidance. A 
pilot study was initially performed with 20 patients to plan for the sample 
size of the study since there was no data from India on the quality of life after 
sclerotherapy.  
 
A sample size of 50 was found to be required, to detect a change of 1cm of 
lesion size from pre-sclerotherapy size after 6 months following 
sclerotherapy with a standard deviation (SD) of 2.5 cm and 80% power with 
a 5% level of significance using paired t test. 
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TOOLS USED: 
A standardised questionnaire called the SF-36 was used, which is a widely 
used tool for assessing quality of life. This was modified after the pilot study 
in 20 patients, to modify the questionnaire to suit the Indian population. 
This questionnaire consisted of assessment in 4 domains- which included 
pain, regional symptoms (related to the location of venolymphatic 
malformation) including activities of daily living (ADL), psychological 
which included morale issues related to the malformation and the cosmetic 
issues especially the malformations in the head and neck region. This 
modified SF-36 questionnaire is attached in the appendix of this manuscript. 
To objectively assess for any decrease in size of the vascular malformation, a 
few regional MRI sequences were done in patients who had returned for 
follow up. 
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Detailed diagrammatic Algorithm of the study 
 
On being referred by various departments for assessment in intervention 
radiology for considering treatment, the patient was seen in the interventional 
radiology consultation room where history taking, and clinical examination 
would be done along with ultrasonography and colour Doppler studies to 
determine the presence of vascular spaces, and pattern of blood flow within. 
 
Day 1
•Clinical examination
•Administer  quality of life questionnaire
PROCEDURE
•DSA & percutaneous sclerotherapy done under General anaesthesia
DAY 1 Post 
procedure
•Clinical examination
•Administer  quality of life questionnaire
DAY 3 Post 
procedure
•Clinical examination
•Administer  quality of life questionnaire
DAY 7 Post  
procedure
•Clinical examination
•Administer  quality of life questionnaire
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The questionnaire was administered to them at multiple stages of the 
treatment plan: pre-procedure, and on day 1, 3 and 7 after the procedure. 
Follow up was advised for all patients between 6 weeks and 6 months after 
the procedure, during which the same questionnaire would be administered to 
ascertain the long-term outcome of quality of life. 
For patients who came for follow up and agreed to undergo MR imaging, a 
few MRI sections were performed to objectively assess the reduction in size 
in the vascular malformation. 
 
DATA PROCESSING & STATISTICAL ANALYSIS: 
The data was collected in terms of variables such as general demographics, 
type of malformation (venous, venolymphatic, pure lymphatic), location, 
maximal dimension, quality of life scores and post sclerotherapy quality of 
life scores. All these variables were entered in a spreadsheet program such as 
MS-Excel 2018®. The software used for data entry was Epidata ®. Data 
analysis was done using SPSS (IBM corporation® version 23). Bibliography 
was managed used Zotero(Centre at George Mason University®).  
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RESULTS 
 
DESCRIPTIVE RESULTS 
 
Distribution of age: 
The range of ages of the patients in this study was 2-47 years with a mean of 
15.8 years with a standard deviation of 10 years.  
 
 
 
 
 
Figure 1: This is a box plot showing the age distribution. The 
interquartile range (25th – 75th centile) ranged between 10 – 22 years 
with a median age of 14 years. There were 2 outliers, both at age of 
47 years. 
 81 | P a g e  
 
Gender: 
Almost equal distribution of females and males with slightly higher female 
preponderance noted (57 %) in this study. 
 
 
 
  
43%
57%
GENDER DISTRIBUTION
male female
Figure 2: Pie chart showing near equal distribution of males and 
females in this study with a slightly higher female predominance 
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LOCATION: 
The location of the slow flow vascular malformation was broadly divided 
into  
1. Extremity 
2. Head and neck region 
3. Trunk – which included chest and abdomen  
 
 
 
 
0
5
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20
25
Trunk Extremity Head and neck Combined
Figure 3: Bar diagram showing the distribution of 
slow flow malformations by region 
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There were near equal distribution of extremity and head and neck slow flow 
vascular malformations in this study. The most common location of 
extremity slow flow vascular malformation was the lower limb. Among the 
head and neck slow flow malformations in this study, many lesions involved 
the tongue, lip and oral mucosa with an equal distribution in the neck 
especially the lymphatic malformations which presented as large macro-
lymphatic malformations in the neck with multiple deep spaces of the neck 
being involved. 
 
PLANE OF THE SLOW FLOW VASCULAR 
MALFORMATIONS: 
All patients prior to the sclerotherapy had an MRI scan of that region, which 
was used for prior planning, for assessing the depth of the lesion from the 
skin, specific regions such as head and neck malformations for involvement 
of the airway for specific anaesthetic risks as all the sclerotherapy for these 
procedures were carried out under general anaesthesia. 
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The planes of involvement were broadly classified as: 
1. Superficial – involvement of the skin and subcutaneous tissue only. 
2. Deep – partial inclusion of the muscles of the entire compartment. 
3. Near complete involvement of the muscles of the compartment. 
4. Juxta-articular / intra-osseous / thoracic cavity / peritoneal 
involvement. 
This classification was used to help evaluate these slow flow malformations, 
to be used for further subgroup analysis. 
 
 
 
0
5
10
15
20
25
30
Superficial only Partial involement
of muscles of
compartment
Near complete
muscle involvement
Juxta articular /
intraosseous /
truncal cavity
Combination of
superficial and
partial muscle
involvement
Figure 4: Bar diagram showing the plane of the malformation based on pre-therapy 
MRI  
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 Majority of the venous malformations, especially the extremity-located VM 
had a partial involvement of the muscles of their respective compartments. 
 
TYPE OF SLOW FLOW VASCULAR MALFORMATION: 
The lesions on MRI were further subclassified based on specific imaging 
features if they were venous, lymphatic or venolymphatic malformation. This 
subdivision was important as it determined the addition of intralesional 
Bleomycin along with sodium tetradecyl sulphate which was the primary 
sclerosant of choice. 
 
 
 
77%
21%
2%
Type of slow flow vascular 
malformations
Venous malformation
Veno-lymphatic malformation
Lymphatic malformation
Figure 5: Pie diagram showing the type of slow flow vascular malformations 
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MAXIMAL DIMENSION ON PRE-TREATMENT MRI: 
As part of the initial work up prior to sclerotherapy, regional MRI scan was 
done to plan treatment. Specifically, fat supressed sequences were used to 
delineate these vascular malformations as they would be hyperintense 
compared to the background fat, soft tissue and bone. A maximal dimension 
was taken in any of the standard orthogonal planes, in whichever plane was 
the largest. This was further used for analysis. The range of size of the lesion 
varied from 1.7 – 44 cm with an interquartile range (25th -75th centile) of 3- 
11cms, with a median size of 6 cm.  
 
 
 
Figure 6: Box plot showing the maximum dimension of the slow flow vascular 
malformation in the pre-treatment MRI. Range of size of the lesion varied from 
1.7 – 44 cm with an interquartile range (25th -75th centile) of 3- 11cms, with a 
median size of 6 cm 
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ANALYTICAL RESULTS: 
 
1. STATISTICAL RELATIONSHIP BETWEEN AGE & QUALITY 
OF LIFE: 
ANOVA (analysis of variance) and logistic regression were used to analyse 
the statistical difference between age at presentation and quality of life scores 
at day 7. This showed a statistically significant difference (p=0.019), with a 
Pearson coefficient of 0.320, suggesting moderate correlation) between the 
age of presentation and quality of life scores, suggesting that patients with 
earlier age of presentation had a better quality of life. 
 
2. STATISTICAL RELATIONSHIP BETWEEN GENDER AND 
QUALITY OF LIFE 
Independent sample T test was used to assess if there was any statistical 
significance between the gender and the outcome following sclerotherapy. 
There was no statistical significant difference between the 2 genders 
(p=0.856) 
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3. STATISTICAL DIFFERENCE IN MEANS OF QUALITY OF LIFE 
AT DIFFERENT POINTS: 
The mean quality of life (QOL) scores were calculated at 3 points of the 
follow up, at day 1, 3 and 7th day post sclerotherapy was calculated. The 
Wilks’s lambda score was used which showed a statistically significant 
difference (p<0.001) between the means of the quality of life pre-
sclerotherapy and day 3 and day 7 of sclerotherapy.  
 
 Mean Std. Deviation N 
Score Day 1 pre- sclero 
15.34 3.605 53 
Score Day 1 post sclero 
17.72 3.313 53 
Score day 3 sclero 11.21 2.514 53 
Day 7 score 10.32 2.352 53 
 
Table 1: This is a table showing the mean and the standard deviation 
of the quality of life scores among the study subjects 
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TESTS USED                Value        F   p value 
 Wilks lambda  0.0094 160.894 <0.0001 
Pillai's trace 0.906 160.894 <0.0001 
 
 
 
Relationship with time: 
The mean quality of life scores showed an increase on day1 post 
sclerotherapy, which subsequently remained higher than pre-sclerotherapy 
scores on day 3, and showed a decrease in scores on day 7, less than the 
baseline score. This is elucidated in the graph given below. The X-axis 
contains the different time points at which quality of life was assessed. On 
the x-axis, the point ‘1’ refers to the day 1 pre-sclerotherapy, ‘2’ refers to day 
1 post sclerotherapy, ‘3’ refers to day 3 post sclerotherapy, and ‘4’ refers to 
day 7 post sclerotherapy. 
The Y-axis contains the average of all the quality of life scores. 
 
 
Table 2: Wilks’s lambda test was used the statistical test used 
for comparing the means pre and post sclerotherapy which 
showed a statistically significant difference 
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4. RELATIONSHIP BETWEEN QUALITY OF LIFE & LOCATION 
OF MALFORMATION: 
ANOVA (analysis of variance) test was used to specifically assess if there 
was any association between the final quality of life (as assessed on day 7) 
TABLE 3 : Graph showing the quality of life scores versus time. This 
shows a temporary worsening at day 1 post sclerotherapy which comes 
back to lesser than baseline pre-sclerotherapy scores 
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and the specific location (either head & neck, extremity or trunk) which did 
not reveal a statistically significant relationship (p=0.359). 
A subgroup analysis was done to look for any relationship between the 
different planes (for example skin and subcutaneous plane involvement only, 
partial involvement of muscles, complete involvement of muscles, intra-
thoracic/abdominal or joint involvement) that were involved on pre-
sclerotherapy MRI and final quality of life ANOVA was used and it showed 
that there was no statistically significant difference between the groups (p= 
0.639). 
 
5. RELATIONSHIP BETWEEN TYPE OF SLOW FLOW 
MALFORMATION AND QUALITY OF LIFE: 
Non-parametric tests like the independent samples Kruskal -Willis test was 
used to assess the relationship between the different types of slow flow 
vascular malformations (VM, VLM, LM) & the quality of life. There was no 
statistical difference (p=0.242) between the different types of slow flow 
vascular malformations & quality of life.  
 
 92 | P a g e  
 
6. RELATIONSHIP BETWEEN NUMBER OF NEEDLES USED & 
QUALITY OF LIFE: 
Logistic regression was used to analyse if there was any statistical difference 
between the number of needles used for sclerotherapy and quality of life at 
day 7 post-procedure. It revealed no significant correlation (Pearson 
regression coefficient of 0.010- poor correlation, p value of 0.942) between 
the number of needles and day 7 quality of life. 
 
7. RELATIONSHIP BETWEEN PRE-TREATMENT SIZE & 
QUALITY OF LIFE: 
The ANOVA test was used to assess if there was a relationship between pre-
sclerotherapy size of the lesion and the quality of life on day 7. It revealed 
no significant correlation (p value = 0.622) between the pre-treatment size 
and day 7 quality of life. 
 
 
 
 93 | P a g e  
 
8. RELATIONSHIP BETWEEN VOLUME OF SCLEROSANT FOAM 
INJECTED AND QUALITY OF LIFE: 
Logistic regression and ANOVA were used to look for any statistical 
correlation between the volume of foam sclerosant injected and quality of life 
on day 7. It showed a statistically significant correlation (p value of 0.031, 
Pearson coefficient of 0.297, showing a moderate strength of association) 
between the volume of sclerosant injected and quality of life on day 7. The 
ANOVA results are given below: 
 
 
    
VOLUME 
INJECTED Sum of Squares Mean Square P value 
Regression 25.346 25.346 .031b 
Residual 262.201 5.141   
Total 287.547     
 
 
TABLE 4: Table showing the ANOVA test to correlate between the 
volume of foam sclerosant injected and quality of life score 
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SUMMARY OF ANALYTICAL STATISTICS: 
 
Number  Relationship between variables  p value 
1 Age & quality of life 0.019 
2 Gender & quality of life 0.856 
3 
Difference in means pre and post sclerotherapy 
QOL (day 7)        <0.0001 
4 Location of the malformation & quality of life 0.359 
5 Plane of malformation & quality of life 0.639 
6 Type of malformation & quality of life 0.242 
7 
No of needles used for sclerosant injection & 
QOL 0.942 
8 Pre-treatment size & quality of life 0.622 
9 Volume of sclerosant foam & quality of life 0.031 
Table 5: Summary of all the clinico-radiological variables with quality of life 
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DISCUSSION 
 
DISCUSSION OF QUALITY OF LIFE AFTER TREATMENT: 
This study demonstrated that there was a statistical difference between the 
mean quality of life scores pre-sclerotherapy and post sclerotherapy (p 
<0.001). This was comparable to prior studies which were done earlier by 
Riita Rautio and their group in Finland (17) & Long Li et al (24) who had 
used similar clinical outcomes and criteria. 
 
FACTORS DETERMINING OUTCOME: 
The analysis looked at multiple clinical and radiological factors which could 
determine the quality of life. 
An earlier age at which sclerotherapy is done was associated with a better 
quality of life (P=0.019). The Pearson coefficient of 0.320 is suggestive of 
moderate strength of correlation. This was comparable to the study done by 
Riita Rautio and their group in Finland (17) which showed a similar 
conclusion. 
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Significant correlation (p=0.031) was also noted between the volume of 
foam sclerosant used and the quality of life outcomes.  
The sclerosant (sodium tetradecyl sulphate) was made into a foam by mixing 
with an equal amount of air. The maximum volume of sclerosant which can 
be used in clinical practice is based on the weight of the patient and is 
1ml/kg. 
Larger size of the lesions sometimes warrants a higher volume of sclerosant 
to be used. However, especially in the lesions of the head and neck, higher 
volume is associated with increased risk of complications in view of 
increased vascularity and proximity to the vital structures such as the airway 
which would require stay in the intensive care unit and thereby increase 
overall morbidity.  
In this study, two patients had complications of the lip and tongue, in which 
there was necrosis and blackish discoloration. This required hospital 
admission and some debridement by the surgeons and wound care. Both 
wounds healed completely without any further complication. Thus, although 
this study demonstrated a better quality of life with higher volume of 
sclerosant injected, the final decision should be made on table by the 
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interventional radiologist performing the procedure after comparing the risks 
and benefits. 
There was no statistically significant difference between the location and the 
quality of life (p=0.359). This is different compared to earlier studies (17) 
that showed that head and neck lesions had a poorer outcome in terms of 
quality of life. 
In this study there was no statistically significant difference (p=0.659) 
between the anatomical plane of the slow flow malformation and the quality 
of life. This is different compared to earlier studies by Riitta et al (17)which 
showed that extremity malformations with a near complete involvement of 
the muscles of the compartment showed a poorer outcome in comparison to 
the ones with superficial or partial muscular compartment involvement. 
There was no statistical association between the type of slow flow 
malformation and outcome (p=0.242). Although there have been no studies 
in this regard, venous malformations due to the involvement of the muscular 
compartment can cause significant pain & reduce the quality of life. 
There was no statistical association between the quality of life and the pre-
treatment size of the lesion (p=0.622). Although in earlier studies by Riitta et 
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al (17) there was an association between the size and quality of life- larger 
size corresponding to poorer outcome 
There was no statistical association between gender, the number of needles 
used for sclerosant injection. 
TEMPORAL PROFILE POST-SCLEROTHERAPY:
 
This graph elucidates the patient’s quality of life post-sclerosant injection. It 
shows that there is a worsening of quality of life scores immediately 
following sclerotherapy, following which, there is a decrease at day 3 and 
decreases further on day 7. This can be explained by fact that there is 
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inflammation of the endothelium and the surrounding tissues due to the 
sclerosant injection. This leads to worsening of pain and worsening of 
regional symptoms. This phenomenon should be explained to the patient and 
their family prior to sclerotherapy as apparent worsening of appearance or 
symptoms post-procedure can cause further apprehension. 
This worsening immediately can be managed with non-steroidal anti-
inflammatory agents and good hydration as there is an improvement within 
48 hours usually. 
COMPLICATIONS: 
Most patients in this study had minor pain and worsening of the swelling 
after the sclerosant injection which was managed conservatively with 
NSAIDs and local symptomatic measures. 
However, there were 2 patients who had developed skin necrosis. Both these 
patients had venous malformations involving the head and neck. The first 
patient was a 16-year-old male with venous malformation involving the lip 
and lower face. He developed blackish discoloration of the lesion the next 
day following sclerotherapy. He was re-admitted into the hospital, required 
debridement of the necrotic tissues with a flap cover by plastic surgery 
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department. The rest of his follow up period was uneventful, and he is 
currently on follow up. 
The second patient was a 14-year-old girl with venous malformation of the 
tongue and lip, who developed black discoloration of the tongue and lower 
lip, who was re-admitted to the hospital, and required debridement. Her post-
operative period was also uneventful, and she is on follow up.  
The third was a patient was 11-year-old boy with a presumed venolymphatic 
malformation of the left side of the face, neck involving the parapharyngeal 
and parotid spaces who underwent one session of foam sclerotherapy. The 
child was well post procedure & on follow up 6 months later was operated by 
the paediatric surgeons. The biopsy revealed a predominant venolymphatic 
malformation with a focus of low grade muco-epidermoid carcinoma. On 
reviewing the imaging there were no solid enhancing components within the 
multicystic lesion. 
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SUMMARY AND CONCLUSIONS 
 
This study demonstrates that sclerotherapy for slow flow vascular 
malformations is a safe and reliable way to alleviate the symptoms of the 
patients. Accurate delineation of the lesion before treatment facilitates the 
planning the appropriate therapy. To achieve optimal results a 
multidisciplinary approach with interventional radiology, dermatologists, 
surgeons, and anaesthetists is often necessary. Sodium tetradecyl sulphate 
and Bleomycin are effective sclerosants for therapy. 
This study demonstrated a few clinical and radiological factors of favourable 
outcome. Earlier age of first sclerotherapy was associated with a significantly 
better outcome in terms of quality of life. Although a significant association 
was demonstrated between the volume of foam sclerosant injected and better 
quality of life, there should be a careful use of sclerosant, especially in the 
head of neck region (lip and tongue) where there is a higher risk of tissue 
necrosis. Complete cure may never be possible in larger lesions, but 
sclerotherapy is an effective remedy for alleviating the patient’s symptoms. 
Patients should be counselled regarding the natural course of events, where 
there is a significant worsening of the symptoms immediately after 
sclerotherapy due to the local inflammatory response.  
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APPENDIX 3 – Child information sheet – English
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APPENDIX 3 – PATIENT INFORMATION SHEET, CONSENT & ASSENT 
FORMS – Child information sheet Telugu
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APPENDIX 3 – Child information sheet – Tamil 
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APPENDIX -3 CHILD INFORMATION SHEET – HINDI 
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APPENDIX 3 – Child assent form- ENGLISH 
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APPENDIX 3 – Child assent form – Telugu 
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APPENDIX 3 – Child assent form – Tamil 
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APPENDIX 3 – Child assent form –Hindi 
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APPENDIX – INFORMATION SHEET ADULT – TAMIL
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APPENDIX 4 – QUESTIONNAIRE USED (Modified SF-36) 
 
Questionnaire for patients with venous malformations (slow flow vascular 
malformations) 
 
The following questions relate to a certain number of 
symptoms, sensations or discomforts that can make everyday 
life difficult. For each symptom listed we ask you to answer 
the corresponding question in the following manner: 
 
Please indicate whether you have experienced what is 
described in the sentence, and if so, to what intensity. 
   
1. If you have felt pain, what was the intensity of this pain? 
No pain Light pain Moderate 
pain 
 
 
Strong 
pain 
 
 
Intense 
pain   
1 2 3 
 
4 
 
5 
    
2. To what extent did you feel bothered/limited in your work or other daily activities because 
of your problem? 
 
    Not 
limited 
A little 
limited 
Moderately 
limited 
     Very 
limited 
Extremely    
limited 
1 2 3 4 5 
 
3. Have you slept badly because of your problems, and how often? 
 
Never Seldom Fairly often Very often Every 
night 
1 2 3 4 5 
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To what extent did your problems bother/limit you while doing the 
movements or activities listed below? 
 
 Not 
bothered/ 
limited at 
all 
      A little 
bothered/ 
limited 
Moderately          
bothered 
    Very 
bothered
/limited 
Impossible    
to do 
4. Standing for a long 
time 
1 2 3 4 5 
5. Climbing stairs 1 2 3 4 5 
6. Crouching, kneeling 1 2 3 4 5 
7. Walking briskly 1 2 3 4 5 
8. Travel by car, 
bus, plane 
 
 
 
 
 
 
 
 
 
 
1 2 3 4 5 
9. Housework such 
as working in the 
kitchen, carrying 
a child, cleaning 
floors, doing 
ironing 
1 2 3 4 5 
10. Going to 
weddings, 
parties 
1 2 3 4 5 
11.  Sporting activities 1 2 3 4 5 
  
Problems can also influence one’s morale. To what extent do the following sentences 
correspond to the way you have felt? 
 
12 
 
 
I feel myself nervous 
Not at all 
 
1 
A little 
 
2 
Moderately 
 
3 
A lot 
 
4 
Absolute 
 
5 
13 I become tired quickly 1 2 3 4 5 
14 I feel I am a burden 
to people 
1 2 3 4 5 
15 I must always be 
careful with my 
extremity 
1 2 3 4 5 
16 I am embarrassed to 
show my extremity 
1 2 3 4 5 
17 I get irritated easily 1 2 3 4 5 
18 I feel handicapped 1 2 3 4 5 
19 I do not feel like going out 1 2 3 4 5 
20 
 
 
 
 
 
20 
I feel myself depressive 1 2 3 4 5 
 
 
       
   20.     ADL (Toilet care, household)       1                      2                    3                  4               5  
 
   21. Regional symptoms        -                  1                      2                    3                 4               5 
(Head and neck- turning neck 
  Upper limb – lifting objects 
Lower limb – Walking, running) 
  
 
APPENDIX 5 – DATA ENTRY SHEET – EXCEL 
SPREADSHEET 
 
hospital number
age
sex
location
Specific locations 
Maximal dimension - pre - sclero MRI (cm)
type
score Day 1 pre- scleroScore Day 1 post sclero
score day 3 scleroday 7 score
No of needles usedSclerosant used
Total volume injected (ml)
Major complications
Minor complications
Further sessions
Details of further sessions
055850H
2m
1- left thigh
2
3.8VM
11
18
10
9
3
2
4
n
n
1
845926G
4m
2- neck and masticator
1 & 2
5.8VLM
13
15
10
10
2
2
4.4
n
n
1
873372G
7f
3 & 1 - right gluteal and abdominal3 & 4
7.7VM
15
17
11
10
2
2
10.2
n
n
1
616944G
9m
3 - axilla
2
16VLM
19
21
15
12
1
2
10.5
n
n
1
024338H
10f
1 - left foot
1 & 2
4.5VM
18
22
10
10
2
2
8.6
n
n
1
070248H
35f
2 -Right neck
2
5.9VLM
15
23
11
10
3
2
13
n
n
1
908989G
14f
2 - left parotid
1 & 2
4.5VLM
11
13
11
10
3
2
8.5
n
n
21 more 10 + 6
022089H
1f
3 -  chest wall
1 & 2
6.7VLM
12
17
12
10
2
1
6
n
n
1
117188H
1m
2- Left submandibular
1 & 2
11.1VLM
8
13
6
6
4
1
18
n
n
21 more 16 ml
893296G
3f
1 - thumb
2
2.7VM
15
17
11
11
2
1
2
n
n
1
193653H
3m
2 -Right cheek 
1 & 3
10.8VM
13
23
9
9
5
1
15
n
n
1
842795G
6f
1 -  thigh
2
1.7VM
17
14
14
12
5
1
6.5
n
n
23 more sessions
885075G
6f
2 - left cheek & orbit
2
5.5VM
11
14
11
11
2
1
5
n
n
1
833499G
7m
2- parotid
1 & 2
2.7VLM
15
14
11
9
3
1
6
n
n
1
812327G
8f
2- chin and submandibular
1 & 2
3.4VLM
15
13
10
10
3
1
4
n
n
21 more 12 ml
129242H
8m
3 -Right chest wall
4
9.2VM
12
20
8
8
3
1
7.5
n
n
1
074778H
9f
1 -Right leg
2
12.5VM
16
19
10
10
2
1
4
n
n
21 more 6 ml
774710g
10m
3 - abdomen
2
5.8VM
15
11
9
9
5
1
11
n
n
21 more 5.5 ml
695731G
10f
1 -  thigh
2
16VM
18
19
11
10
2
1
3
n
n
1
631735g
11f
1 - forearm
1 & 2
23.7VM
19
18
13
12
4
1
5.5
N
N
21 more session
084213H
11f
3- retroperitoneum
2
6.7VLM
16
19
10
10
3
1
3
n
n
1
092987G
11m
1 -Left lower limb
2
22.2VM
13
17
9
9
4
1
18
n
n
1
690101G
12m
3 & 1 -Trunk + Upper limb
1 & 3
23VLM
18
20
11
11
4
1
21
n
n
21 more 38 ml kt syndrome
919939G
12m
1- medial thigh
2
4.5VM
12
15
12
10
2
1
4
n
n
1
083190H
13m
2 -  parotid and neck
1 & 2
4.5VM
17
21
12
11
2
1
1.5
n
n
1
273038C
15m
1- thigh
1
16.6LM
22
20
15
14
2
1
4
n
n
1
904090G
15F
1 - left lower limb
1 & 2
4.4VM
15
18
12
12
2
1
2
n
n
1
924121G
15m
2 - left submandibular
2
5.5VM
13
16
12
11
5
1
9
n
n
1
107358H
15m
3 -Right chest 
2
6VM
9
14
7
6
2
1
8
n
n
1
079043G
16F
1 - Upper limb forearm
2
7.5VM
19
20
16
14
2
1
2
n
n
21 more 2 ml
894750G
16f
1 - right calf
3
21.2VM
14
17
11
10
4
1
12
n
n
22 more sessions
135617H
16f
1 -left leg
2
3.5VM
20
22
10
10
2
1
3
n
n
1
834685g
17f
1 -  thigh
2
6.3VM
17
12
11
8
2
1
4
n
n
22 more sessions 
890719G
17f
2 - tongue and  submandibular
2
4.4VM
14
16
12
11
4
1
9
n
n
21 more 4 ml
903574G
18f
2- left cheek and lip
1 & 2
2.7VM
17
18
12
12
2
1
3.5
n
n
21 more 3.5 ml
011902H
18m
3 -intra-abdominal
4
13.8VM
18
21
13
13
2
1
5
n
n
21 more 2 ml
099954H
18f
1 - Left thigh
2
8.8VM
12
18
9
8
2
1
2
n
n
21 more 3 ml
127588H
18f
1 -Left lower limb
4
3.3VM
15
21
9
8
3
1
8
n
n
1
048099H
19m
1- Right thigh
2
3.6VM
22
23
11
9
3
1
7
n
n
1
852589G
22f
1 - forearm
3 & 4
11.9VM
17
19
11
11
7
1
7
n
n
11 more 8 ml
610489G
22f
3 - abdomen
1
3.9VM
16
18
14
12
2
1
2.5
n
n
1
948671G
22m
3 & 1 - left ul and chest wall
3 & 4
44VM
12
15
10
9
3
1
21
n
n
1
485134G
23m
2 - submandibular
1 & 2
12VM
20
21
17
15
4
1
8
N
N
1
500129C
23m
2 - Right frontal region
3
16.2VM
14
17
9
9
3
1
10
n
n
1
116432H
26f
3 - Left chest wall
2
4.4VM
11
19
7
7
3
1
5
n
n
1
630913g
27m
2 -  lip
1
2.9VM
16
12
12
9
2
1
4
debridement
discoloration
1
929892G
27m
1 - foot
2
4VM
18
20
15
14
3
1
4
n
n
1
947213G
28f
2 - right neck
2
7.4VM
11
15
9
7
2
1
5
n
n
1
020300H
29f
2 -Right supraclavicular
2
7.2VM
12
18
11
10
3
1
7
n
n
21 more 8 ml
540285G
35m
2 -  face( masseter)
2
2.3VM
20
20
11
11
1
1
2
n
n
1
837519g
47f
2 - cheek
2
5.1VM
16
14
12
10
2
1
7.5
debridement
discoloration
1
820426G
47f
1 -  thigh
2
7.7VM
27
26
20
20
3
1
4
n
n
1
943047G
4f
3 - left axilla and chest
3
12.9VLM
12
16
9
8
3
2
19.2
n
n
21 more 10  + 3 units
1- extremity
1- superficial (skin and subcutaneous)
VM - venous malformation
1 - STS only
5 units of bleomycin - 1ml
2- head and neck
2- deep -partial involvement of muscles of the compartment
VLM - venolymphatic malformation
2 - STS & bleomycin
3 - trunk
3 - Near complete involvement of muscles of the compartment
LM- Lymphatic malformation
4- Juxta-articular / intra-osseous / intraabdominal / thoracic involvement
  
 
